Macquarie Group LTD Harmony Biosciences Holdings, Inc. Transaction History

Macquarie Group LTD

$85.1 Billion
Q2 2024

A detailed history of Macquarie Group LTD transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 295,880 shares of HRMY stock, worth $10.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

295,880

Previous 299,906 1.34%

Holding current value

$10.4 Million

Previous $10.1 Million 11.36%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$28.81 - $33.01 $115,989 - $132,898	-4,026 Reduced 1.34%	295,880 $8.93 Million
Q1 2024 May 14, 2024	SELL	$29.93 - $35.06 $8.25 Million - $9.66 Million	-275,646 Reduced 47.89%	299,906 $10.1 Million
Q4 2023 Feb 14, 2024	SELL	$19.2 - $33.78 $7.24 Million - $12.7 Million	-376,841 Reduced 39.57%	575,552 $18.6 Million
Q3 2023 Nov 14, 2023	BUY	$31.89 - $39.03 $1.62 Million - $1.99 Million	50,865 Added 5.64%	952,393 $31.2 Million
Q2 2023 Aug 14, 2023	BUY	$30.5 - $37.4 $2.22 Million - $2.72 Million	72,859 Added 8.79%	901,528 $31.7 Million
Q1 2023 May 15, 2023	BUY	$30.8 - $53.92 $3.9 Million - $6.82 Million	126,575 Added 18.03%	828,669 $27.1 Million
Q4 2022 Feb 21, 2023	BUY	$45.4 - $60.91 $1.87 Million - $2.51 Million	41,250 Added 6.24%	702,094 $38.7 Million
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $1.29 Million - $1.7 Million	30,633 Added 4.86%	660,844 $29.3 Million
Q2 2022 Aug 15, 2022	BUY	$33.54 - $52.15 $7.54 Million - $11.7 Million	224,843 Added 55.47%	630,211 $30.7 Million
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $13.4 Million - $20.7 Million	405,368 New	405,368 $19.7 Million

Others Institutions Holding HRMY

# of Institutions

237

Shares Held

45.5M

Call Options Held

48.2K

Put Options Held

56.5K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.08B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Harmony Biosciences Holdings, Inc. Transaction History